Cipher Pharmaceuticals Inc. (T:CPH)
Business Focus: Pharmaceuticals (NEC)
Sunny as of November 01, 2023
For the latest outlook, get the company report
You may also be interested in
Insider Filings
Latest 10 SEDI filings for CPH within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
See Short Report
Loading...
Company News
Nov 24, 2023 16:00 ET
Cipher Pharmaceuticals Announces Change of Auditor
MISSISSAUGA, ON, Nov. 24, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it has changed its auditors from Ernst & Young LLP ("Former Auditor") to RSM Canada LLP ("Successor Auditor") effective November 23, 2023. At the request of the Company, the Former Auditor resigned as the auditor of the Company effective November 23, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective November 23, 2023, until the next Annual General Meeting of the Company.
Nov 15, 2023 16:00 ET
Cipher Pharmaceuticals Announces Normal Course Issuer Bid
MISSISSAUGA, ON, Nov. 15, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").
Valuation Ratios
Industry
Sector
Beta
1.00
--
--
Price to Sales - TTM
5.59
3.70
2.75
Price to Book - most recent quarter
1.53
1.84
1.59
Price to Cash Flow per share - TTM
3.51
7.28
10.44
Price to Free Cash Flow per share - TTM
7.85
8.19
18.82
Short Report
| Date | Number of Shares Shorted | Net Change |
|---|---|---|
| Nov 15, 2023 | 159,908 | 133,301 |
| Oct 31, 2023 | 26,607 | 3,205 |
| Oct 15, 2023 | 23,402 | -9,646 |
Business Summary
| Sector: Healthcare | Industry: Pharmaceuticals |
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.